Skip to main content

Advertisement

Log in

Practice Patterns in the Use of Anti-Tumor Necrosis Factor Alpha Agents in the Management of Crohn’s Disease: A US National Practice Survey Comparing Experts and Non-Experts

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

The US Food and Drug Administration currently approves three types of anti-tumor necrosis factor α (anti-TNFα) therapy for treatment of moderate to severe Crohn’s disease. There are no guidelines to clarify which of the drugs may be better suited to individual clinical scenarios.

Aims

We gathered national data on the prescribing pattern, comfort levels, and algorithms gastroenterologists use for management of their biologic-requiring Crohn’s disease patients.

Methods

An internet survey was mailed to members of the American Gastroenterology Association. Responses were separated into “non-expert” and “expert” physician groups on the basis of whether a practice consisted of >50% of patients with inflammatory bowel disease. We compared experts with non-experts with regard to the use of the three anti-TNF agents, attitudes regarding their relative efficacy, and their experience with adverse events.

Results

Of 3,990 eligible gastroenterologists, 473 replied in full (11.9%). Sixty (12.6%) respondents met the criterion for IBD expert physician. Experts were comfortable using both immunomodulators and anti-TNFα therapy. Community physicians were equally comfortable prescribing 6-mercaptopurine, azathioprine, infliximab, and adalimumab, but less comfortable than experts with methotrexate (56 vs. 86%, P < 0.05) and certolizumab (68 vs. 89%, P < 0.05). Expert physicians were much more likely to have encountered adverse reactions to anti-TNFα therapy.

Conclusions

Our results suggest that experts are more comfortable using a broader array of medical therapy than non-expert physicians. Although both groups had similar concerns regarding side-effects of anti-TNFα therapy, expert physicians were much more likely to have managed a broad range of complications in their patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035.

    Article  PubMed  CAS  Google Scholar 

  2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549. doi:S0140-6736(02)08512-4[pii]10.1016/S0140-6736(02)08512-4.

    Article  PubMed  CAS  Google Scholar 

  3. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333. doi:quiz591S0016-5085(05)02315-2[pii]10.1053/j.gastro.2005.11.030.

    Article  PubMed  CAS  Google Scholar 

  4. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239. doi:gut.2006.106781[pii]10.1136/gut.2006.106781.

    Article  PubMed  CAS  Google Scholar 

  5. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2:912–920. doi:S1542356504004148[pii].

    Article  PubMed  CAS  Google Scholar 

  6. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238. doi:357/3/228[pii]10.1056/NEJMoa067594.

    Article  PubMed  CAS  Google Scholar 

  7. Schwartz DA. The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: an interview with David A Schwartz, 13 June 2007. Biologics. 2008;2:126–128.

    PubMed  Google Scholar 

  8. Mushlin AI, Ghomrawi H. Health care reform and the need for comparative-effectiveness research. N Engl J Med. 2010;362:e6.

    Article  PubMed  Google Scholar 

  9. Donovan M, Lunney K, Carter-Pokras O, et al. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci. 2007;52:1798–1805.

    Article  PubMed  CAS  Google Scholar 

  10. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332:292–297.

    Article  PubMed  CAS  Google Scholar 

  11. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.

    Article  PubMed  CAS  Google Scholar 

  12. El Mourabet M, El-Hachem S, Harrison JR, et al. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets. 2010;11:234–241.

    Article  PubMed  CAS  Google Scholar 

  13. Mahadevan U, Kane S. Use of infliximab in pregnancy. Am J Gastroenterol. 2010;105:219. author reply 219-20.

    Article  PubMed  Google Scholar 

  14. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:283–311.

    Article  PubMed  CAS  Google Scholar 

  15. Oussalah A, Roblin X, Laharie D, et al. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Aliment Pharmacol Ther. 2009;30:854–863.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arun Swaminath.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swaminath, A., Lebwohl, B., Capiak, K.M. et al. Practice Patterns in the Use of Anti-Tumor Necrosis Factor Alpha Agents in the Management of Crohn’s Disease: A US National Practice Survey Comparing Experts and Non-Experts. Dig Dis Sci 56, 1160–1164 (2011). https://doi.org/10.1007/s10620-010-1530-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-010-1530-9

Keywords

Navigation